Tarsus Pharmaceuticals develops and sells eye care treatments, including XDEMVY for an eyelid condition caused by mites. It last closed at $73.01 on Nov 20, down 6.00% on the day. The next earnings report for TARS is expected around Mon, Feb 22, 2027, after the close. For the quarter ended Sep 2026, TARS reported EPS of -$14.40 on revenue of $194.6M, with revenue up 63.9% from a year ago. Over its last 8 reports the stock moved an average of 6.9% the session after earnings. Over the last 12 months TARS insiders bought $0 of stock on the open market and sold $20.8M, according to SEC Form 4 filings.
AI Auto Pilots
Is TARS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold TARS.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on TARSStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
TARS · as of the Nov 20 close · updated each morning
Moving sideways
The stock is 1% below its 20 day and 1% below its 50 day average. It is 6% above its 200 day average, so the longer trend is still up. Momentum is improving (RSI 48). The nearest support is the Pivot S1 at $71.02, and the nearest resistance the swing high (Oct 22) at $73.11.
Short trendNeutral
Long trendBullish
MomentumImproving
StretchNormal
VolatilityHigh, 5.2%/day
Key levels
$91.5352 week high+25.4%
$76.56Pivot R1+4.9%
$74.56Pivot+2.1%
$74.0950 day average+1.5%
$73.7620 day average+1.0%
$73.11Swing high (Oct 22)+0.1%
$73.01Last close
$71.02Pivot S1−2.7%
$70.85100 day average−3.0%
$69.47Swing low (Aug 27)−4.8%
$68.27200 day average−6.5%
$53.8952 week low−26.2%
Indicators
RSI (14)
47.66
Middle of its range
Neutral
MACD
1.05
Above its signal line
Bullish
Stochastic
63.7
Middle of its range
Neutral
ADX (14)
17.5
No clear trend
Williams %R
-52.1
Oversold below −80, overbought above −20
Neutral
CCI (20)
19.9
Oversold below −100, overbought above 100
Neutral
Rate of change
+6.4%
Change over 10 sessions
Bullish
ATR (14)
$3.83
Typical daily range, 5.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
Uptrend
Short trendBullish
Long trendBullish
MomentumFading
StretchNormal
VolatilityNormal, 11.0%/day
Key levels
$91.5352 week high+25.4%
$76.56Pivot R1+4.9%
$74.56Pivot+2.1%
$74.0950 day average+1.5%
$73.7620 day average+1.0%
$73.11Swing high (Oct 22)+0.1%
$73.01Last close
$71.02Pivot S1−2.7%
$70.85100 day average−3.0%
$69.47Swing low (Aug 27)−4.8%
$68.27200 day average−6.5%
$53.8952 week low−26.2%
Indicators
RSI (14)
51.97
Middle of its range
Neutral
MACD
2.12
Below its signal line
Bearish
Stochastic
40.8
Middle of its range
Neutral
ADX (14)
23.2
Weak trend
Williams %R
-70.7
Oversold below −80, overbought above −20
Neutral
CCI (20)
53.9
Oversold below −100, overbought above 100
Neutral
Rate of change
−7.9%
Change over 10 sessions
Bearish
ATR (14)
$8.04
Typical daily range, 11.0% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for TARS
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how TARS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow TARS usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for TARSHow many large options trades hit TARS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in TARS in the last 90 days.
From SEC Form 4 filings by TARS's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TARS is in one of them and how their past TARS trades turned out.
Tarsus Pharmaceuticals is a biopharmaceutical company based in Irvine, California, focused on developing and selling treatments for eye care. Its main product, XDEMVY, is an eye solution approved in the United States for Demodex blepharitis, an inflammation of the eyelids caused by mites. The company markets this product to eye care professionals and is developing other treatments, including candidates for ocular rosacea and for preventing Lyme disease.